Overview

The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
Adult Patients with Severe Sepsis
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Drotrecogin alfa activated
Protein C